A groundbreaking international collaboration, fortified by a prestigious pan-European EUREKA grant, has been officially launched to pioneer the development of…
Read More
Closing the Information Gap: ETH Zürich Team Integrates Function and Binding in One Drug Screening Assay
A groundbreaking development from a collaborative team at ETH Zurich and Karolinska Institutet promises to revolutionize early-stage drug discovery by…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry faces an escalating crisis marked by soaring costs, protracted timelines, and persistently low success rates in bringing…
Read More
Terray says TerraBind delivers 26x faster inference than Boltz-2 by skipping diffusion-based coordinate generation
Terray Therapeutics, a burgeoning startup based in the Los Angeles area, has unveiled TerraBind, a groundbreaking potency prediction model designed…
Read More
From List Price to Net Price: How Finance Leaders Decode Real Drug Costs
In the intricate landscape of the healthcare industry, the discourse surrounding drug pricing frequently fixates on the list price. Public…
Read More
How digital tools and AI are accelerating drug discovery
The pharmaceutical industry stands at a critical juncture, grappling with escalating costs and protracted timelines in the arduous journey of…
Read More
FDA Refuses to Review Moderna’s mRNA Flu Vaccine Application, Citing Comparator Study Design
Washington D.C. – Moderna, a leading biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has issued…
Read More
SLAS 2026: Orchestration platforms, API-first instruments and the rise of semiautonomous labs
The SLAS (Society for Laboratory Automation and Screening) 2026 conference, held in Boston from February 7-11, marked a pivotal moment…
Read More
Novo Nordisk sues Hims for GLP-1 patent infringement
In a significant escalation of an ongoing commercial and regulatory dispute, pharmaceutical giant Novo Nordisk has filed a lawsuit against…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
For decades, the medical community has grappled with the persistent challenge of mood disorders, offering successive waves of antidepressants that,…
Read More
